Illumina Inc
USUSDIllumina Inc (US:ILMN) — Medical Specialities. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.
À propos de l'entreprise
- Site web
- illumina.com
- Secteur
- Health Care · Medical Specialities
- Siège social
- San Diego, United States
- Employés
- 9 250
- Fondée
- 1998
- Actions en circulation
- 151 M au 2026-07-24
- Flottant
- 149.78 M
- Capitalisation boursière
- 41.33 Md USD
- Initiés
- 0.21%
- Investisseurs institutionnels
- 106.47%
- Secteur d'activité (SIC)
- Laboratory Analytical Instruments
- ISIN
- US4523271090
- LEI
- SQ95QG8SR5Q56LSNF682
Description
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Dividendes
| Date ex | Versement | Montant | % | Type | Ticker |
|---|---|---|---|---|---|
| 2024-06-25 | — | 3.1051 USD | 1.1/1.1 % | — | LSE:0J8Z |
Actualités de cette semaine
Communiqués de presse du site de l'entreprise pour les investisseurs, mis à jour chaque jour. Les liens mènent au site de l'entreprise. Les titres sont dans la langue originale, comme sur le site web de l'entreprise.
Principaux actionnaires
| Détenteur | Participation | Actions | Date du rapport |
|---|---|---|---|
| Blackrock Inc. | 12.71% | 19.19 M | 2026-06-30 |
| Capital World Investors | 10.22% | 15.43 M | 2026-06-30 |
| Vanguard Portfolio Manag… | 4.39% | 6.63 M | 2026-06-30 |
| Vanguard Capital Managem… | 4.36% | 6.59 M | 2026-06-30 |
| State Street Corporation | 4.31% | 6.51 M | 2026-06-30 |
| WCM Investment Managemen… | 4.11% | 6.21 M | 2026-06-30 |
| iShares Trust-iShares Co… | 3.51% | 5.3 M | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 3.02% | 4.56 M | 2026-06-30 |
| FMR, LLC | 3% | 4.52 M | 2026-06-30 |
| AQR Capital Management,… | 2.35% | 3.54 M | 2026-06-30 |
| Primecap Management Comp… | 2.33% | 3.51 M | 2026-06-30 |
| AMERICAN BALANCED FUND | 2.31% | 3.49 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.18% | 3.3 M | 2026-06-30 |
| Geode Capital Management… | 1.95% | 2.95 M | 2026-06-30 |
| Growth Fund of America | 1.82% | 2.74 M | 2026-06-30 |
| New Economy Fund | 1.78% | 2.68 M | 2026-06-30 |
| VANGUARD HORIZON FUNDS-V… | 1.17% | 1.76 M | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 1.15% | 1.74 M | 2026-06-30 |
| WASHINGTON MUTUAL INVEST… | 1.04% | 1.57 M | 2026-07-31 |
| NEW PERSPECTIVE FUND | 0.93% | 1.4 M | 2026-06-30 |
| THAYSEN JACOB (Chief Exe… | ≈0.07% | 109 073 | 2026-03-05 |
| CUNNINGHAM EVERETT V (Of… | ≈0.03% | 50 840 | 2025-03-05 |
| BARNARD STEVEN (Chief Te… | ≈0.03% | 41 335 | 2026-03-05 |
| DHINGRA ANKUR (Chief Fin… | ≈0.02% | 34 264 | 2026-03-05 |
| PEGELS KEVIN CARL (Offic… | ≈0.02% | 29 038 | 2026-03-05 |
| SCHILLER PHILIP W (Direc… | ≈0.01% | 22 220 | 2026-05-21 |
| EPSTEIN ROBERT S (Direct… | ≈0.01% | 22 139 | 2025-05-21 |
| LECKMAN PATRICIA L (Offi… | ≈0.01% | 21 259 | 2026-06-05 |
| ARNOLD FRANCES H PH.D. (… | ≈0.01% | 20 907 | 2025-05-21 |
| MEISTER KEITH A (Directo… | — | — | 2026-09-04 |
